Osteoporosis is one of the most difficult problems in the management of Chronic Juvenile Arthritis (JCA). The available data suggest that bone loss results from multifactorial processes which lead to bone degradation through the activation of osteoclasts. Biphosphonates are synthetic factors that, once localized on the surface of hydroxyapatite crystals, do not allow either the production or destruction of the crystals. This activity seems to be due to cytotoxicity against osteoclasts and to inhibition of prostaglandin E2 synthesis. There is some evidence that these drugs are effective in the treatment of osteoporosis in several diseases. In an attempt to reduce or prevent osteoporosis in children affected by JCA we started a trial with disodium clodronate, a type of biphosphonate. Thirteen patients were enrolled in the study: 7 received disodium clodronate and 6 acted as control subjects. Before starting the therapy and after one year we performed a CT scan to evaluate the mineral bone density in all patients. The mean bone density increased from a bone mineral content of 129 mg/cc before treatment to 134 mg/cc after treatment (8% increase); control patients passed from 123 mg/cc to 115 mg/cc (7% decrease) in the same period. Only one child stopped treatment because of gastrointestinal side effects. The small number of patients enrolled in the trial does not allow any definite conclusions to be drawn, but the data are interesting and worthy of further study.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Macrophage Inhibitor Clodronate Enhances Liver Transduction of Lentiviral but Not Adeno-Associated Viral Vectors or mRNA Lipid Nanoparticles in Neonatal and Juvenile Mice.
Cells
November 2024
Great Ormond Street Institute of Child Health, University College London, London WC1E 1EH, UK.
Recently approved adeno-associated viral (AAV) vectors for liver monogenic diseases haemophilia A and B are exemplifying the success of liver-directed viral gene therapy. In parallel, additional gene therapy strategies are rapidly emerging to overcome some inherent AAV limitations, such as the non-persistence of the episomal transgene in the rapidly growing liver and immune response. Viral integrating vectors such as in vivo lentiviral gene therapy and non-viral vectors such as lipid nanoparticles encapsulating mRNA (LNP-mRNA) are rapidly being developed, currently at the preclinical and clinical stages, respectively.
View Article and Find Full Text PDFSystemic Clodronate Liposome Treatment for Depletion of Blood-Contacting Phagocytes and Investigation of Their Role in the Control of Bunyavirus Viremia.
Methods Mol Biol
December 2024
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
During viral infection, phagocytic cells participate in numerous immunological processes. A common approach to elucidate the specific contributions of phagocytic cells is through direct comparison of viral pathogenesis of phagocyte-depleted and phagocyte-intact animals. Clodronate liposomes are a versatile and simple means of depleting phagocytes in any animal model.
View Article and Find Full Text PDFValidity evaluation of a rat model of monoiodoacetate-induced osteoarthritis with clinically effective drugs.
BMC Musculoskelet Disord
November 2024
Central Research Laboratory, Research & Development Division, Seikagaku Corporation, Tateno 3-1253, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Background: Knee osteoarthritis (KOA) is the most common type of joint disease in elderly people and is characterized by pain and dysfunction. Although the monoiodoacetate (MIA)-induced model is widely used as a rodent KOA model, it is important to acknowledge the inherent limitations of this model, as the MIA model develops complex pathological phases on a daily basis. An accurate understanding of this model and the selection of an appropriate time point according to the target for drug candidates can lead to the development of clinically effective drugs.
View Article and Find Full Text PDFDepletion of macrophages and osteoclast precursors mitigates iron overload-mediated bone loss.
IUBMB Life
January 2025
Department of Medicine III & Center for Healthy Aging, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Iron is an essential element for physiological cellular processes, but is toxic in excess. Iron overload diseases are commonly associated with low bone mass. Increased bone resorption by osteoclasts as well as decreased bone formation by osteoblasts have been implicated in bone loss under iron overload conditions.
View Article and Find Full Text PDFFavorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats.
Pediatr Surg Int
November 2024
Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Article Synopsis
- This study looked at how clodronate, which affects vesicular nucleotide transport, impacts liver inflammation linked to intestinal failure in rats with short bowel syndrome.
- The researchers used a rat model that involved feeding them through a vein and surgically removing most of their small intestine, then giving them different doses of clodronate.
- Results showed that high doses of clodronate reduced liver fat and inflammation in the rats, suggesting potential benefits for patients with similar conditions related to intestinal failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!